CA3152699C - Methods for treatment of nephrotic syndrome and related conditions - Google Patents

Methods for treatment of nephrotic syndrome and related conditions Download PDF

Info

Publication number
CA3152699C
CA3152699C CA3152699A CA3152699A CA3152699C CA 3152699 C CA3152699 C CA 3152699C CA 3152699 A CA3152699 A CA 3152699A CA 3152699 A CA3152699 A CA 3152699A CA 3152699 C CA3152699 C CA 3152699C
Authority
CA
Canada
Prior art keywords
angpti4
polypeptide
proteinuria
nephrotic syndrome
rats
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3152699A
Other languages
English (en)
French (fr)
Other versions
CA3152699A1 (en
Inventor
Sumant S. CHUGH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/841,240 external-priority patent/US9139629B2/en
Application filed by Individual filed Critical Individual
Priority to CA3207108A priority Critical patent/CA3207108A1/en
Publication of CA3152699A1 publication Critical patent/CA3152699A1/en
Application granted granted Critical
Publication of CA3152699C publication Critical patent/CA3152699C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3152699A 2013-03-15 2014-03-15 Methods for treatment of nephrotic syndrome and related conditions Active CA3152699C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3207108A CA3207108A1 (en) 2013-03-15 2014-03-15 Methods for treatment of nephrotic syndrome and related conditions

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/841,240 US9139629B2 (en) 2010-06-05 2013-03-15 Methods for treatment of nephrotic syndrome and related conditions
US13/841,240 2013-03-15
CA2906982A CA2906982C (en) 2013-03-15 2014-03-15 Methods for treatment of nephrotic syndrome and related conditions

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2906982A Division CA2906982C (en) 2013-03-15 2014-03-15 Methods for treatment of nephrotic syndrome and related conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3207108A Division CA3207108A1 (en) 2013-03-15 2014-03-15 Methods for treatment of nephrotic syndrome and related conditions

Publications (2)

Publication Number Publication Date
CA3152699A1 CA3152699A1 (en) 2014-09-18
CA3152699C true CA3152699C (en) 2023-09-05

Family

ID=51537930

Family Applications (3)

Application Number Title Priority Date Filing Date
CA3152699A Active CA3152699C (en) 2013-03-15 2014-03-15 Methods for treatment of nephrotic syndrome and related conditions
CA2906982A Active CA2906982C (en) 2013-03-15 2014-03-15 Methods for treatment of nephrotic syndrome and related conditions
CA3207108A Pending CA3207108A1 (en) 2013-03-15 2014-03-15 Methods for treatment of nephrotic syndrome and related conditions

Family Applications After (2)

Application Number Title Priority Date Filing Date
CA2906982A Active CA2906982C (en) 2013-03-15 2014-03-15 Methods for treatment of nephrotic syndrome and related conditions
CA3207108A Pending CA3207108A1 (en) 2013-03-15 2014-03-15 Methods for treatment of nephrotic syndrome and related conditions

Country Status (8)

Country Link
EP (1) EP2970416B1 (enExample)
JP (1) JP2016516726A (enExample)
KR (1) KR102221041B1 (enExample)
CN (1) CN105229024A (enExample)
AU (1) AU2014233219B2 (enExample)
CA (3) CA3152699C (enExample)
NZ (1) NZ712935A (enExample)
WO (1) WO2014145275A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017111215A1 (ko) * 2015-12-21 2017-06-29 주식회사 브레인온 기억력, 학습력, 인지력 향상용 조성물
KR101706296B1 (ko) 2015-12-21 2017-02-13 주식회사 브레인온 기억력, 학습력, 인지력 향상용 조성물
CN112689762B (zh) * 2018-06-01 2024-08-23 美国控股实验室公司 用于lc-ms/ms蛋白质组学基因分型的方法和系统
IL279497B2 (en) * 2018-06-22 2024-12-01 Synact Pharma Aps Treatment of proteinuria

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2574791A1 (en) * 2004-07-20 2006-02-09 Genentech, Inc. Compositions and methods of using angiopoietin-like 4 protein
US20110301103A1 (en) * 2010-06-05 2011-12-08 Chugh Sumant S Methods of Treatment
EP2575858B1 (en) * 2010-06-05 2017-12-20 Chugh, Sumant S. Methods for treatment of nephrotic syndrome and related conditions
US9475850B2 (en) * 2010-06-05 2016-10-25 The Uab Research Foundation Methods for treatment of nephrotic syndrome and related conditions

Also Published As

Publication number Publication date
CA3152699A1 (en) 2014-09-18
CA2906982A1 (en) 2014-09-18
AU2014233219A1 (en) 2015-10-08
EP2970416C0 (en) 2023-11-22
KR102221041B1 (ko) 2021-02-25
CN105229024A (zh) 2016-01-06
NZ712935A (en) 2020-03-27
AU2014233219B2 (en) 2018-02-22
CA2906982C (en) 2022-05-31
WO2014145275A1 (en) 2014-09-18
KR20150140686A (ko) 2015-12-16
HK1220213A1 (en) 2017-04-28
EP2970416A4 (en) 2017-02-22
JP2016516726A (ja) 2016-06-09
CA3207108A1 (en) 2014-09-18
EP2970416B1 (en) 2023-11-22
EP2970416A1 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
EP2575858B1 (en) Methods for treatment of nephrotic syndrome and related conditions
US9475850B2 (en) Methods for treatment of nephrotic syndrome and related conditions
CA2906982C (en) Methods for treatment of nephrotic syndrome and related conditions
US11866468B2 (en) Methods for treatment of nephrotic syndrome and related conditions
AU2017200933A1 (en) Methods of treatment
HK1220213B (en) Methods for treatment of nephrotic syndrome and related conditions
HK1252916B (en) Use of an angiopoietin-like 4 (angptl4) polypeptide in the manufacture of a medicament for the treatment of proteinuria.

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220316

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250205

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250205

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250205

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260211

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260212